FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979908215> ?p ?o ?g. }

• W2979908215 endingPage "858" @default.
• W2979908215 startingPage "858" @default.
• W2979908215 abstract "Abstract SerpinA3N, a serine protease inhibitor, has been shown to ameliorate neuropathic pain by inhibiting leukocyte elastase activity (Vicuña et al., Nature Med 2015, 21:518-523). Patients with sickle cell disease (SCD) have activated leukocytes and experience neuropathic pain. We observed that SerpinA3N protein expression is significantly reduced in the dorsal root ganglion (DRG) of 5 month old homozygous HbSS-BERK sickle mice, compared to age-matched HbAA-BERK control mice expressing normal human hemoglobin A (p < 0.05). Since HbSS-BERK sickle mice demonstrate tonic hyperalgesia (Kohli et al., Blood 2010, 116:456-465), we hypothesize that decreased expression of SerpinA3N contributes to hyperalgesia by increasing elastase activity in these mice. We examined our hypothesis by using both genders of HbSS-BERK sickle and HbAA-BERK control mice, treated intravenously with and without sivelestat, a small molecule inhibitor of elastase. Mechanical, thermal and musculoskeletal/deep tissue hyperalgesia were analyzed before (considered baseline, BL) and after treatments. Elastase activity was determined using a fluorescent elastase substrate MeOSuc-AAPV-AMC (EMD Milipore). We observed that elastase activity is significantly increased in the DRG and lungs of male and female sickle mice compared to gender and age-matched control mice (p < 0.05 and < 0.005 for female and male DRG, respectively; p < 0.001 and < 0.05 for female and male lungs, respectively). Thus, decreased SerpinA3N expression perhaps contributes to increased elastase activity in sickle mice. Treatment of sickle mice with a single dose of 2 mg/Kg sivelestat led to a significant decrease in mechanical, heat and cold hyperalgesia for up to 24 hours compared to BL (p < 0.05), but no effect was noted in deep tissue hyperalgesia. Increasing the single dose to 4.5 mg/Kg led to a significant decrease in mechanical and thermal as well as deep tissue hyperalgesia for up to 24 hours in both genders compared to BL or saline treated mice (p < 0.05). Continuation of treatment with sivelestat 4.5 mg/Kg/day for 3 days led to significantly reduced hyperalgesia for up to 6 days in both genders of mice. These findings suggest that elastase activity contributes to nociceptive mechanisms, since hyperalgesia remained reduced for up to 3 days even after discontinuation of sivelestat. Reduced hyperalgesia following 3 days of sivelestat (4.5 mg/Kg/day) treatment was accompanied by a significant decrease in elastase activity in the DRG (p < 0.005) and lungs (p < 0.05) of both genders of sickle mice compared to saline treatment, but no histopathological changes were observed in lungs, kidney, liver, spleen and heart. Activating transcription factor 3 (ATF3), a marker of neuropathic pain, is elevated in the DRG of sickle as compared to control mice (Vincent et al., Blood 2013, 122:1853-1862). Sivelestat treatment significantly reduced ATF3-immunoreactivity compared to saline treatment in the DRG of sickle mice (p < 0.05), suggesting a decrease in neuronal injury which underlies neuropathic pain. None of the treatments had any effect on control mice. Sivelestat treatment showed no significant effect on serum tryptase or cutaneous mast cell degranulation in sickle or control mice. Thus, sivelestat specifically inhibits elastase activity. However, both elastase and tryptase activate protease-activated receptor-2 (PAR2) in the peripheral nervous system, stimulating the release of pro-nociceptive neuropeptides and activation of transient receptor potential vanilloid (TRPV) channels, leading to hyperalgesia. Since PAR-2 and TRPV channels are activated in sickle mice, it is likely that sivelestat treatment has an inhibitory effect on these mechanisms. It has been suggested that leukocytes, including activated neutrophils, contribute to acute lung injury (a common complication of SCD) and the pathogenesis of SCD (Zhang et al., Blood 2016, 127:801-809). Our observations that decreased SerpinA3N protein expression leads to increased elastase activity in DRG and lung in sickle mice suggest that this mechanism may contribute to sickle pathobiology and pain. In Japan, sivelestat is already approved for treatment of acute lung injury. Therefore, pharmacological inhibition of elastase may offer the advantage of treating chronic pain while concomitantly ameliorating one of the pathogenic mechanisms of SCD. Disclosures No relevant conflicts of interest to declare." @default.
• W2979908215 created "2019-10-18" @default.
• W2979908215 creator A5004649512 @default.
• W2979908215 creator A5008956413 @default.
• W2979908215 creator A5018863416 @default.
• W2979908215 creator A5023852362 @default.
• W2979908215 creator A5064474713 @default.
• W2979908215 creator A5084976151 @default.
• W2979908215 date "2016-12-02" @default.
• W2979908215 modified "2023-10-16" @default.
• W2979908215 title "Regulation of Elastase By SerpinA3N Contributes to Pain in Sickle Cell Disease" @default.
• W2979908215 doi "https://doi.org/10.1182/blood.v128.22.858.858" @default.
• W2979908215 hasPublicationYear "2016" @default.
• W2979908215 type Work @default.
• W2979908215 sameAs 2979908215 @default.
• W2979908215 citedByCount "8" @default.
• W2979908215 countsByYear W29799082152017 @default.
• W2979908215 countsByYear W29799082152018 @default.
• W2979908215 countsByYear W29799082152019 @default.
• W2979908215 countsByYear W29799082152021 @default.
• W2979908215 crossrefType "journal-article" @default.
• W2979908215 hasAuthorship W2979908215A5004649512 @default.
• W2979908215 hasAuthorship W2979908215A5008956413 @default.
• W2979908215 hasAuthorship W2979908215A5018863416 @default.
• W2979908215 hasAuthorship W2979908215A5023852362 @default.
• W2979908215 hasAuthorship W2979908215A5064474713 @default.
• W2979908215 hasAuthorship W2979908215A5084976151 @default.
• W2979908215 hasConcept C10162356 @default.
• W2979908215 hasConcept C105702510 @default.
• W2979908215 hasConcept C126322002 @default.
• W2979908215 hasConcept C134018914 @default.
• W2979908215 hasConcept C140530291 @default.
• W2979908215 hasConcept C15490471 @default.
• W2979908215 hasConcept C170493617 @default.
• W2979908215 hasConcept C181199279 @default.
• W2979908215 hasConcept C203014093 @default.
• W2979908215 hasConcept C2776281502 @default.
• W2979908215 hasConcept C2777107010 @default.
• W2979908215 hasConcept C2778620579 @default.
• W2979908215 hasConcept C2779134260 @default.
• W2979908215 hasConcept C2779245659 @default.
• W2979908215 hasConcept C2779668550 @default.
• W2979908215 hasConcept C2780976302 @default.
• W2979908215 hasConcept C2781044401 @default.
• W2979908215 hasConcept C42219234 @default.
• W2979908215 hasConcept C55493867 @default.
• W2979908215 hasConcept C71924100 @default.
• W2979908215 hasConcept C86803240 @default.
• W2979908215 hasConceptScore W2979908215C10162356 @default.
• W2979908215 hasConceptScore W2979908215C105702510 @default.
• W2979908215 hasConceptScore W2979908215C126322002 @default.
• W2979908215 hasConceptScore W2979908215C134018914 @default.
• W2979908215 hasConceptScore W2979908215C140530291 @default.
• W2979908215 hasConceptScore W2979908215C15490471 @default.
• W2979908215 hasConceptScore W2979908215C170493617 @default.
• W2979908215 hasConceptScore W2979908215C181199279 @default.
• W2979908215 hasConceptScore W2979908215C203014093 @default.
• W2979908215 hasConceptScore W2979908215C2776281502 @default.
• W2979908215 hasConceptScore W2979908215C2777107010 @default.
• W2979908215 hasConceptScore W2979908215C2778620579 @default.
• W2979908215 hasConceptScore W2979908215C2779134260 @default.
• W2979908215 hasConceptScore W2979908215C2779245659 @default.
• W2979908215 hasConceptScore W2979908215C2779668550 @default.
• W2979908215 hasConceptScore W2979908215C2780976302 @default.
• W2979908215 hasConceptScore W2979908215C2781044401 @default.
• W2979908215 hasConceptScore W2979908215C42219234 @default.
• W2979908215 hasConceptScore W2979908215C55493867 @default.
• W2979908215 hasConceptScore W2979908215C71924100 @default.
• W2979908215 hasConceptScore W2979908215C86803240 @default.
• W2979908215 hasIssue "22" @default.
• W2979908215 hasLocation W29799082151 @default.
• W2979908215 hasOpenAccess W2979908215 @default.
• W2979908215 hasPrimaryLocation W29799082151 @default.
• W2979908215 hasRelatedWork W1988171015 @default.
• W2979908215 hasRelatedWork W2021370268 @default.
• W2979908215 hasRelatedWork W2117351537 @default.
• W2979908215 hasRelatedWork W2162721194 @default.
• W2979908215 hasRelatedWork W2349149425 @default.
• W2979908215 hasRelatedWork W2380552259 @default.
• W2979908215 hasRelatedWork W2767026395 @default.
• W2979908215 hasRelatedWork W2884986932 @default.
• W2979908215 hasRelatedWork W2979908215 @default.
• W2979908215 hasRelatedWork W3090342679 @default.
• W2979908215 hasVolume "128" @default.
• W2979908215 isParatext "false" @default.
• W2979908215 isRetracted "false" @default.
• W2979908215 magId "2979908215" @default.
• W2979908215 workType "article" @default.